---
figid: PMC4650980__gov052f1p
figlink: /pmc/articles/PMC4650980/figure/gov052-F1/
number: Figure 1
caption: 'Receptor tyrosine kinases and their targeted therapies in gastroesophageal
  cancers: EGFR, VEGFR and MET. The EGFR family of receptor tyrosine kinases (RTKs)
  includes four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu,
  HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All proteins of this family have an extracellular
  ligand-binding domain, a single hydrophobic transmembrane domain and a cytoplasmic
  tyrosine kinase-containing domain. The intracellular tyrosine kinase domain of EGFR
  receptors is highly conserved, although HER3 lacks kinase activity. HER2 functions
  as a ligand-less receptor and induces hetero-dimerization with other EGFR family
  receptors upon ligand binding, whereas EGFR and HER4 undergo homo-dimerization.
  The subsequent activation of the intrinsic tyrosine kinase domain activates phosphorylation
  cascades, and the downstream effectors include RAF, PI3K and PLC. VEGF and its receptor
  VEGFR promote angiogenesis. The overexpression of VEGF is significantly associated
  with poor prognosis in gastrointestinal cancers. The HGF/MET pathway activates complex
  signaling events that depend on the cellular context and produces a variety of cellular
  responses such as proliferation, motility, angiogenesis and invasion. The MET pathway
  is upregulated in a wide range of human tumors, and this finding often signals a
  poor prognosis.'
pmcid: PMC4650980
papertitle: 'Targeted therapy in gastroesophageal cancers: past, present and future.'
reftext: Janghee Woo, et al. Gastroenterol Rep (Oxf). 2015 Nov;3(4):316-329.
pmc_ranked_result_index: '162344'
pathway_score: 0.9671549
filename: gov052f1p.jpg
figtitle: 'Receptor tyrosine kinases and their targeted therapies in gastroesophageal
  cancers: EGFR, VEGFR and MET'
year: '2015'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4650980__gov052f1p.html
  '@type': Dataset
  description: 'Receptor tyrosine kinases and their targeted therapies in gastroesophageal
    cancers: EGFR, VEGFR and MET. The EGFR family of receptor tyrosine kinases (RTKs)
    includes four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2
    (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All proteins of this family have
    an extracellular ligand-binding domain, a single hydrophobic transmembrane domain
    and a cytoplasmic tyrosine kinase-containing domain. The intracellular tyrosine
    kinase domain of EGFR receptors is highly conserved, although HER3 lacks kinase
    activity. HER2 functions as a ligand-less receptor and induces hetero-dimerization
    with other EGFR family receptors upon ligand binding, whereas EGFR and HER4 undergo
    homo-dimerization. The subsequent activation of the intrinsic tyrosine kinase
    domain activates phosphorylation cascades, and the downstream effectors include
    RAF, PI3K and PLC. VEGF and its receptor VEGFR promote angiogenesis. The overexpression
    of VEGF is significantly associated with poor prognosis in gastrointestinal cancers.
    The HGF/MET pathway activates complex signaling events that depend on the cellular
    context and produces a variety of cellular responses such as proliferation, motility,
    angiogenesis and invasion. The MET pathway is upregulated in a wide range of human
    tumors, and this finding often signals a poor prognosis.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFB
  - VEGFA
  - PLCB4
  - BRAF
  - PLCZ1
  - PLCE1
  - VEGFC
  - ERBB3
  - HRAS
  - MAPK3
  - RAF1
  - PLCB2
  - PLCB3
  - AKT1
  - AKT2
  - AKT3
  - FLT1
  - FLT4
  - ARAF
  - ERBB2
  - PRKCZ
  - HGF
  - MAP2K1
  - MAPK1
  - MAP2K2
  - MET
  - PRKD3
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - KDR
  - PRKCQ
  - PRKCH
  - PLCD1
  - PLCD3
  - PLCB1
  - VEGFD
  - PGF
  - EGF
  - PLCG1
  - PLCG2
  - PLCD4
  - AMELX
  - EGFR
  - NRAS
  - PRKCI
  - KRAS
  - PRKCG
  - Regorafenib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB4
  entrez: '5332'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCZ1
  entrez: '89869'
- word: PLCE
  symbol: PLCE
  source: hgnc_alias_symbol
  hgnc_symbol: PLCE1
  entrez: '51196'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: RAS-GTP
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: MEK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB2
  entrez: '5330'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB3
  entrez: '5331'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: MEK/ERK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MEK/ERK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD1
  entrez: '5333'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD3
  entrez: '113026'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB1
  entrez: '23236'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCE1
  entrez: '51196'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD4
  entrez: '84812'
- word: AMG
  symbol: AMG
  source: hgnc_prev_symbol
  hgnc_symbol: AMELX
  entrez: '265'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: RAS-GTP
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: RAS-GTP
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
chemicals:
- word: Regorafenib
  source: MESH
  identifier: C559147
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
